## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced\ 01/07/96\ \ Origin:\ Appendix\ 5\ \ Amended\ 01/07/98,\ 01/09/99,\ 01/07/00,\ 30/09/01,\ 11/03/02,\ 01/01/03,\ 24/10/05,\ 01/08/12,\ 04/03/13,\ 01/08/12,\ 01/08/1$ 

Name of	of entity		
Galan	Lithium Limited		
ABN			
87 149	9 349 646		
We (th	ne entity) give ASX the following informa	ition.	
	<b>Part 1 - All issues</b> ust complete the relevant sections (attach sheet	ts if there is n	ot enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	1. 2. 3.	Class A Performance Shares Class B Performance Shares Unlisted Options
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1. 2. 3.	5,000,000 5,000,000 4,000,000
3	Dain aireal 4		
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	1. 2. 3.	Class A Performance Shares Class B Performance Shares Unlisted options exercisable at \$0.3438 on or before 11 June 2021

4 1. No – upon achieving designated Do the +securities rank equally in milestones, the performance shares will all respects from the +issue date convert to shares and will then rank equally with an existing +class of quoted with existing fully paid ordinary shares. +securities? 2. No – upon achieving designated milestones, the performance shares will If the additional +securities do not convert to shares and will then rank equally rank equally, please state: with existing fully paid ordinary shares. the date from which they do 3. No – upon exercise of options, the shares the extent to which they issued will then rank equally with existing participate for the next fully paid ordinary shares. dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration 1. Nil 2. Nil Nil 6 Purpose of the issue Issued to Managing Director on the (If issued as consideration for the terms and conditions approved by acquisition of assets. shareholders at a general meeting held clearly identify those assets) on 6/6/19 Issued to Managing Director on the terms and conditions approved by shareholders at a general meeting held on 6/6/19 Issued to advisors for services provided under mandates Yes 6a Is the entity an +eligible entity that obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h *in* relation to the +securities the subject of this Appendix 3B, and comply with section 6i 29 November 2018 6b The date the security holder resolution under rule 7.1A was passed 4,000,000 Unlisted options exercisable at 6с Number of +securities issued \$0.3438 on or before 11 June 2021 without security holder approval under rule 7.1 Nil 6d Number of +securities issued with security holder approval under rule

7.1A

<sup>+</sup> See chapter 19 for defined terms.

5,000,000 Class A performance Shares 6e Number of +securities issued with 5,000,000 Class B Performance Shares security holder approval under rule 7.3, or another specific security holder approval (specify date of Both classes of performance shares were approved by shareholders at a general meeting meeting) held on 6/6/19 Nil 6f Number of +securities issued under an exception in rule 7.2 N/A 6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation. N/A 6h If +securities were issued under rule 7.1A for non-cash consideration. state date on which valuation of consideration was released to ASX Market Announcements 23,386,878 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements 7 13 June 2019 <sup>+</sup>Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. Number +Class 129,334,278 Fully paid ordinary shares 8 Number and +class of all +securities (ASX:GLN) quoted on ASX (including the +securities in section 2 applicable) Number +Class Options exercisable at \$0.15 9 Number and \*class of all \*securities 2,825,000 on or before 29 November not quoted on ASX (including the securities in section 2 if applicable) 2019 23,941,178 Options exercisable at \$0.14 on or before 31 December 2019 5,350,000 Options exercisable at \$0.60

on or before 31 August 2020

<sup>+</sup> See chapter 19 for defined terms.

4,000,000	Options exercisable at \$0.3438 on or before 11 June 2021
5,000,000	Class A Performance Shares
5,000,000	Class B Performance Shares

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The Company currently has no dividend policy

## Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the +securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
	rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
	•	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	

<sup>+</sup> See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders
25	If the issue is contingent on *security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do *security holders sell their entitlements in full through a broker?
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?
32	How do <sup>+</sup> security holders dispose of their entitlements (except by sale through a broker)?
33	<sup>+</sup> Despatch date
	3 - Quotation of securities only complete this section if you are applying for quotation of securities
34	
3 <del>4</del>	Type of securities (tick one)
(a)	Securities described in Part 1
(b)	All other securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

<sup>+</sup> See chapter 19 for defined terms.

## Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to docume	to indicate you are providing the information or ments	
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
36	If the *securities are *equity securities, a distribution scheor *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	dule of the additional
37	A copy of any trust deed for the additional *securities	
Entitie	ies that have ticked box 34(b)	
38	Number of securities for which   +quotation is sought	
39	Class of *securities for which quotation is sought	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another security, clearly identify that other security)	

<sup>+</sup> See chapter 19 for defined terms.

Number and \*class of all \*securities quoted on ASX (*including* the securities in clause 38)

Number	+Class

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:		Date: 13 June 2019
	(Company secretary)	

Print name: Mike Robbins

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for †eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	70,090,001	
<ul> <li>Add the following:</li> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	25,000,000 shares (vendors and finders) 16,269,109 shares (GLNOA conversions) 675,000 shares (option conversions \$0.15) 141,176 shares (option conversions \$0.14) 50,000 shares (option conversions \$0.14) 514,706 shares (option conversions \$0.14) 141,176 shares (option conversions \$0.14) 180,891 shares (option underwriting) 14,545,455 shares (placement)	
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	0	
"A"	127,607,514	

Appendix 3B Page 8

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	19,141,127	
Step 3: Calculate "C", the amount of place already been used	ement capacity under rule 7.1 that has	
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	3,000,000 options (vendors) 1,515,000 shares (Acuity) 4,000,000 options (advisors)	
<ul><li>Under an exception in rule 7.2</li><li>Under rule 7.1A</li></ul>		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	8,515,000	
Step 4: Subtract "C" from ["A" x "B"] to counder rule 7.1	alculate remaining placement capacity	
"A" x 0.15 Note: number must be same as shown in Step 2	19,141,127	
Subtract "C"	8,515,000	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	10,626,127	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placem	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	127,607,514	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	12,760,751	
Step 3: Calculate "E", the amount of place already been used	ement capacity under rule 7.1A that has	
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	0	
Step 4: Subtract "E" from ["A" x "D"] to c under rule 7.1A	alculate remaining placement capacity	
"A" x 0.10	12,760,751	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	12,760,751	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.